Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

医学 骨膜炎 哮喘 安慰剂 恶化 内科学 临床终点 支气管扩张剂 生物标志物 嗜酸性粒细胞 喘息 呼出气一氧化氮 随机对照试验 肺活量测定 病理 细胞外基质 化学 替代医学 细胞生物学 生物 生物化学
作者
Nicola A. Hanania,Phillip E. Korenblat,Kenneth R. Chapman,Eric D. Bateman,Petr Kopecký,Pierluigi Paggiaro,Akihito Yokoyama,Julie Olsson,Sarah Gray,Cécile Holweg,Mark D. Eisner,Charles Asare,Saloumeh K Fischer,Kun Peng,Wendy S. Putnam,John G. Matthews
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:4 (10): 781-796 被引量:464
标识
DOI:10.1016/s2213-2600(16)30265-x
摘要

Background In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1 in patients with uncontrolled asthma, particularly in those with high concentrations of type 2 biomarkers (eg, periostin or blood eosinophils). We undertook replicate phase 3 studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controller medication. Methods Adult patients with uncontrolled asthma, pre-bronchodilator FEV1 40–80% predicted, and stable background therapy were randomly assigned (1:1:1) with an interactive voice–web-based response system to receive lebrikizumab 37·5 mg or 125 mg, or placebo subcutaneously, once every 4 weeks. Randomisation was stratified by screening serum periostin concentration, history of asthma exacerbations within the last 12 months, baseline asthma medications, and country. The primary efficacy endpoint was the rate of asthma exacerbations over 52 weeks in biomarker-high patients (periostin ≥50 ng/mL or blood eosinophils ≥300 cells per μL), analysed with a Poisson regression model corrected for overdispersion with Pearson χ2 that included terms for treatment group, number of asthma exacerbations within the 12 months before study entry, baseline asthma medications, geographic region, screening periostin concentration, and blood eosinophil counts as covariates. Both trials are registered at ClinicalTrials.gov, LAVOLTA I, number NCT01867125, and LAVOLTA II, number NCT01868061. Findings 1081 patients were treated in LAVOLTA I and 1067 patients in LAVOLTA II. Over 52 weeks, lebrikizumab reduced exacerbation rates in biomarker-high patients in the 37·5 mg dose group (rate ratio [RR] 0·49 [95% CI 0·34–0·69], p<0·0001) and in the 125 mg dose group (RR 0·70 [0·51–0·95], p=0·0232) versus placebo in LAVOLTA I. Exacerbation rates were also reduced in biomarker-high patients in both dose groups versus placebo in LAVOLTA II (37·5 mg: RR 0·74 [95% CI 0·54–1·01], p=0·0609; 125 mg: RR 0·74 [0·54–1·02], p=0·0626). Pooling both studies, the proportion of patients who experienced treatment-emergent adverse events (79% [1125 of 1432 patients] for both lebrikizumab doses vs 80% [576 of 716 patients] for placebo), serious adverse events (8% [115 patients] for both lebrikizumab doses vs 9% [65 patients] for placebo), and adverse events leading to study drug discontinuation (3% [49 patients] for both lebrikizumab doses vs 4% [31 patients] for placebo) were similar between lebrikizumab and placebo. The following serious adverse events were reported in the placebo-controlled period: one event of aplastic anaemia and five serious adverse events related to raised concentrations of eosinophils in patients treated with lebrikizumab and one event of eosinophilic pneumonia in the placebo group. Interpretation Lebrikizumab did not consistently show significant reduction in asthma exacerbations in biomarker-high patients. However, it blocked interleukin-13 as evidenced by the effect on interleukin-13-related pharmacodynamic biomarkers, and clinically relevant changes could not be ruled out. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiao礼完成签到,获得积分10
刚刚
ppistachio完成签到 ,获得积分10
2秒前
科研通AI6.3的应助被qq采纳,获得10
2秒前
AeAeAe完成签到,获得积分10
3秒前
jifas完成签到,获得积分10
3秒前
stop here完成签到,获得积分10
3秒前
梁凯华完成签到 ,获得积分10
3秒前
张哈哈发布了新的文献求助10
3秒前
4秒前
陈1完成签到 ,获得积分10
4秒前
errui发布了新的文献求助10
4秒前
4秒前
廿一雨完成签到,获得积分10
5秒前
学习永动机完成签到,获得积分10
5秒前
Danger完成签到 ,获得积分10
5秒前
科科完成签到,获得积分10
6秒前
molihuakai的应助被不错吧采纳,获得10
6秒前
zzx123发布了新的文献求助10
7秒前
8秒前
小蘑菇的应助被胖三斤采纳,获得10
8秒前
流苏发布了新的文献求助10
8秒前
凉水完成签到,获得积分10
8秒前
9秒前
迅速河马完成签到,获得积分20
9秒前
9秒前
李健的应助被阳光的半雪采纳,获得10
10秒前
风趣忻完成签到,获得积分20
10秒前
obito发布了新的文献求助10
10秒前
orixero的应助被噫吁嚱采纳,获得10
11秒前
11秒前
11秒前
yue完成签到,获得积分10
12秒前
12秒前
13秒前
14秒前
丘比特的应助被最好的采纳,获得10
14秒前
一杯芝士发布了新的文献求助10
15秒前
桐桐的应助被风中的宛白采纳,获得10
15秒前
15秒前
渣渣兔完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651